Alector (ALEC)
Develops brain-penetrant therapies for neurodegenerative disease through its ABC delivery platform.
Something off on this page? Send us feedback.
Develops neurodegenerative-disease therapies around Alector Brain Carrier, with current work in ABC-enabled antibodies, enzymes, and siRNA. The business has no approved products and depends on collaboration funding, clinical progress, and competition in blood-brain-barrier delivery.
Develops therapies for neurodegenerative disease around Alector Brain Carrier, a blood-brain-barrier delivery platform for antibodies, enzymes, and siRNA. Current ABC-enabled programs include AL037/AL137-ABC in Alzheimer's disease, AL050-ABC in GCase-linked disorders, and AL064/AL164-ABC in tauopathies.
Operates as a one-segment, South San Francisco biotech with no approved products. Revenue comes from collaborations and financing rather than product sales, with GSK and a prior AbbVie alliance shaping the funding history.
Recent late-stage progranulin setbacks reset the portfolio toward wholly owned preclinical and research programs. Execution depends on IND-enabling work, trial progress, and competition with other blood-brain-barrier delivery platforms.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 4, 2026 | Morgan Stanley | Target | Target: — | Target: $2 |
| Apr 15, 2026 | Cantor Fitzgerald | Upgrade | ||
| Mar 10, 2026 | BTIG | Upgrade | ||
| Oct 22, 2025 | H.C. Wainwright | Target | Target: — | Target: $5 |
| Oct 22, 2025 | Mizuho Securities | Target | Target: — | Target: $1.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $172.8M · Total debt $32.8M · Total assets $202.9M · Shareholders' equity −$10.0M
- Revenue
- $3.3M
- Operating income
- −$24.4M
- Net income
- −$23.0M
No dividends on record.
| Institutions | 82.45% | 92.06M shares | |
|---|---|---|---|
| 147 holders · as of Jun 30, 2026 | |||
| Insiders | 8.84% | 9.87M shares | |
| 13 holders · as of Sep 4, 2026 | |||
| Other | 8.71% | 9.73M shares | |
| remainder | |||
111.66M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover Management, LLCInstitution | 8.96% | 10.00M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.03% | 7.85M | as of Jun 30, 2026 |
Arnon Rosenthal1,2Insiderdirector, officer: Chief Executive Officer | 6.70% | 8.21M | filed Sep 4, 2026 |
Acadian Asset Management LLCInstitution | 3.95% | 4.41M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 3.87% | 4.32M | as of Jun 30, 2026 |
- Arnon Rosenthal's transaction reports restate only vehicles that traded; the 2026 ownership statement (8.21M) less the 738.2K net shares sold since is used instead.
- Arnon Rosenthal reports a block also reported by State Street Corp; it is counted once, under State Street Corp.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Arnon Rosenthal | director, officer: Chief Executive Officer | −72,606 | $2.66 |
| Sep 3, 2026 | Neil Lindsay Berkley | officer: CFO & Chief Business Officer | −29,251 | $2.66 |
| Sep 4, 2026 | Grace Wong-Sarad | officer: Principal Accounting Officer | −3,625 | $2.51 |
| Sep 3, 2026 | Grace Wong-Sarad | officer: Principal Accounting Officer | −5,165 | $2.67 |
| Sep 2, 2026 | Grace Wong-Sarad | officer: Principal Accounting Officer | −656 | $2.75 |
- Denali Therapeutics
Transport Vehicle platform and A-beta/GCase overlap
- Arrowhead Pharmaceuticals
CNS siRNA challenger in tau and brain delivery
- Eli Lilly
Commercial anti-amyloid AD therapy benchmark
- Gain Therapeutics
GCase-targeted Parkinson's disease program peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alector | $1.97 | +2.07% | $214.3M | — | — | 15.5 | −57.8% |
| Denali Therapeutics | $21.46 | +4.84% | $3.25B | — | — | 901.4 | — |
| Arrowhead Pharmaceuticals | $71.84 | +4.43% | $9.69B | — | — | 14.5 | +171.0% |
| Eli Lilly | $1,169.04 | +0.36% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Gain Therapeutics | $1.88 | +2.17% | $78.5M | — | — | — | — |
| Median | 39.1 | 28.6 | 14.5 | +109.3% |